Abstract
Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20%) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 320-327 |
| Number of pages | 8 |
| Journal | Experimental and Molecular Pathology |
| Volume | 40 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1984 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Clinical Biochemistry
- Molecular Biology
- Pathology and Forensic Medicine
Cite this
Suppression of weight gain by glucagon in obese Zucker rats. / Chan, Eve K.; Mackey, Maureen A.; Snover, Dale C.; Schneider, Philip D; Rucker, Richard D.; Eugene Allen, C.; Buchwald, Henry.
In: Experimental and Molecular Pathology, Vol. 40, No. 3, 1984, p. 320-327.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Suppression of weight gain by glucagon in obese Zucker rats
AU - Chan, Eve K.
AU - Mackey, Maureen A.
AU - Snover, Dale C.
AU - Schneider, Philip D
AU - Rucker, Richard D.
AU - Eugene Allen, C.
AU - Buchwald, Henry
PY - 1984
Y1 - 1984
N2 - Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20%) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.
AB - Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20%) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.
UR - http://www.scopus.com/inward/record.url?scp=0021261189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021261189&partnerID=8YFLogxK
U2 - 10.1016/0014-4800(84)90049-2
DO - 10.1016/0014-4800(84)90049-2
M3 - Article
C2 - 6723936
AN - SCOPUS:0021261189
VL - 40
SP - 320
EP - 327
JO - Experimental and Molecular Pathology
JF - Experimental and Molecular Pathology
SN - 0014-4800
IS - 3
ER -